Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP slid 7.09% to $6.42 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP advanced 5.76% to $6.79 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index ...

Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s forecast for CRB-913 peak sales has been lowered to ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...

Corbus Pharmaceuticals has a 12 month low of $6.54 and a 12 month high of $61.90. The stock’s fifty day moving average price is $9.98 and its 200-day moving average price is $20.82.

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price target lowered by Jefferies Financial Group from $70.00 to $53.00 in a research report report published on Tuesday,Benzinga reports.